Subtype
Pancreatic Neoplasm
CI-CAN-00001356Explore in graph →
Non-malignant988 active trials8 approved drugs63 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001356Explore in graph →
Clinical trials
4,217 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05196334 | Pharmacotyping of Pancreatic Patient-derived Organoids | recruiting | — | 88 | Herlev HospitalOTHER | 1 | Oct 3, 2024 | clinicaltrials |
| NCT06166147 | A Prospective Study of Liquid Biopsy for Pancreatic Cancer Early Detection | recruiting | — | 276 | Fudan UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04498767 |
| Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)(OligoRARE) |
| recruiting |
| N/A |
| 200 |
| European Organisation for Research and Treatment of Cancer - EORTCNETWORK |
| 7 |
| Aug 26, 2024 |
| clinicaltrials |
| NCT06079346 | A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer(STOP-PC) | recruiting | Phase 2 / Phase 3 | 455 | Oncotelic Inc.INDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06541340 | A New Strategy for Preoperative Drainage of Resectable Pancreatic Head Cancer Combined Severe Obstructive Jaundice(PROB) | recruiting | N/A | 360 | Ruijin HospitalOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06534762 | Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study | recruiting | Phase 2 | 260 | Zhejiang Provincial People's HospitalOTHER | 1 | Aug 2, 2024 | clinicaltrials |
| NCT02021604 | Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma | recruiting | Phase 1 | 250 | Cook Children's Health Care SystemOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06491472 | Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer | recruiting | Phase 2 | 36 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT06454448 | Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT06478225 | Evaluate the Safety and Efficacy of BGT007H Cell Therapy in Patients With Relapsed/Refractory Pancreatic Cancer | recruiting | N/A | 12 | RenJi HospitalOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT06196294 | GPC3/Mesothelin-CAR-γδT Cells Against Cancers | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT03755739 | Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors | recruiting | Phase 2 / Phase 3 | 200 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05187338 | Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05779917 | Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT06359275 | PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients | recruiting | Phase 2 | 81 | Fudan UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05911217 | A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer | recruiting | Phase 1 | 20 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 1 | May 28, 2024 | clinicaltrials |
| NCT06427460 | Central-boost Ablative Radiation Therapy for Solid Tumors (CBART) | recruiting | Phase 2 | 67 | Changhai HospitalOTHER | 1 | May 23, 2024 | clinicaltrials |
| NCT06403735 | A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 250 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2024 | clinicaltrials |
| NCT04493632 | OSPREY is a Post-market, Global, Multicentre, Observational, Prospective Registry.(OSPREY) | recruiting | — | 500 | OncoSil Medical LimitedINDUSTRY | 2 | Apr 30, 2024 | clinicaltrials |
| NCT06391892 | Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery(LIQUIPANC) | recruiting | Phase 3 | 100 | Elisabethinen HospitalOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT05117723 | Intraductal Papillary Mucinous Neoplasm (IPMN) Database - A Tool to Predict Pancreatic Cancer(MAPS) | recruiting | — | 1,000 | St Vincent's Hospital MelbourneOTHER | 1 | Apr 18, 2024 | clinicaltrials |
| NCT06349278 | Pancreatic Cancer and Synchronous Liver Metastases Resection Following Neoadjuvant FOLFIRINOX(PDAC-LIV) | recruiting | N/A | 15 | Laval UniversityOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT05187312 | Registry for Advanced Endoscopy(ERDB) | recruiting | — | 1,000 | Region StockholmOTHER_GOV | 1 | Apr 12, 2024 | clinicaltrials |
| NCT05714124 | Liver Embolization Approaches for Tumor Management(LEATUM) | recruiting | — | 580 | IRCCS San RaffaeleOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06111274 | A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer | recruiting | Phase 2 | 82 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Apr 11, 2024 | clinicaltrials |
| NCT06361316 | Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer | recruiting | N/A | 53 | Kuirong JiangOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT05984810 | NIR-Fluorescence Guided Surgical Resection of Neoadjuvant Treated Localized Pancreatic Cancer Using SGM-101(FLUOPANC-II) | recruiting | Phase 2 | 20 | Leiden University Medical CenterOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT06340620 | EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope | recruiting | N/A | 140 | Orlando Health, Inc.OTHER | 1 | Apr 1, 2024 | clinicaltrials |
| NCT06145074 | Examining Safety, Efficacy and Feasibility of Preoperative Propranolol in Patients With PDAC.(IMPULS) | recruiting | Phase 2 | 30 | Zealand University HospitalOTHER | 1 | Mar 28, 2024 | clinicaltrials |
| NCT06326736 | Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer | recruiting | Early Phase 1 | 12 | Jinling Hospital, ChinaOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT06196788 | Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer(PTCA199-9) | recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Mar 21, 2024 | clinicaltrials |
| NCT06151262 | A Study of Trilaciclib Combined With mFOLFIRINOX in the Treatment of Patients With Advanced Pancreatic Cancer | recruiting | Phase 2 | 30 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT05988814 | Trial Evaluating the Efficacy and the Safety of FOLFIRINOX3 Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer in First Line of Chemotherapy(FOLFIRINOX3 P) | recruiting | Phase 2 | 90 | Centre Georges Francois LeclercOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT05794048 | METabolic PROFILE of Hepatocarcinoma and Pancreatic Tumors(PROMETHEP) | recruiting | N/A | 300 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06245330 | A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 180 | Ascentawits Pharmaceuticals, LtdINDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06229340 | Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations(NТО-RAS) | recruiting | Phase 2 | 20 | N.N. Petrov National Medical Research Center of OncologyOTHER | 1 | Jan 29, 2024 | clinicaltrials |
| NCT06159478 | Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume)(Perfume) | recruiting | Phase 2 | 32 | National Cancer Center, JapanOTHER_GOV | 1 | Dec 13, 2023 | clinicaltrials |
| NCT06160596 | Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis(ROSALIND) | recruiting | — | 1,020 | Cure 51OTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT06017284 | Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer(PTCA199-5) | recruiting | Phase 3 | 100 | Fudan UniversityOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT06126406 | Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors | recruiting | Phase 1 | 60 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Nov 13, 2023 | clinicaltrials |
| NCT04575363 | RPSA as a Potential Prognostic Biomarker of Pancreatic Cancer(PaCaBioMarkeR) | recruiting | N/A | 90 | CHU de ReimsOTHER | 1 | Nov 9, 2023 | clinicaltrials |
| NCT06010862 | Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors | recruiting | Phase 1 | 36 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Nov 8, 2023 | clinicaltrials |
| NCT05752812 | The HELPP Score: A Pretreatment Score to Predict Survival in Pancreatic Cancer | recruiting | — | 1,500 | Medical University of ViennaOTHER | 1 | Oct 27, 2023 | clinicaltrials |
| NCT05916261 | Personalized Tumor Vaccines and Pabolizumab in Patients With Advanced Pancreatic Cancer | recruiting | Early Phase 1 | 54 | Ruijin HospitalOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT06065891 | Para-aortic Lymph Node Metastasis in Resectable Pancreatic Cancer(PALN) | recruiting | N/A | 300 | Jon UnossonOTHER | 2 | Oct 4, 2023 | clinicaltrials |
| NCT06055010 | Improving Pancreatic Cancer Care by the Use of Computational Science and Technology(IMPACT) | recruiting | — | 5,000 | UMC UtrechtOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT06043466 | A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors | recruiting | Phase 1 | 30 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06043921 | Multicenter Study of Circulating Tumor DNA in Patients With Pancreatic Cancer Using a Personalized Panel(ARTEMIS-PC) | recruiting | — | 150 | Invitae CorporationINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06028724 | A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)(POPCORN) | recruiting | — | 782 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Sep 13, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Oct 3, 2024source: clinicaltrials